Phase 1b/2a diSArm trial evaluating AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia  LOS ANGELES, July 30, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $5.25 million of non-dilutive funding ...

LOS ANGELES, July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will deliver a presentation at Viruses of Microbes 2024, which is being held July 15-19, 2024, in Cairns, Australia.   Details of the presentation are as follo ...

Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES, March 4, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportun ...

LOS ANGELES, Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D., Chief Medical Officer, will deliver a presentation at the 6th Annual Bacteriophage Therapy Summit, which is being held February 27-29 in Boston. Details of the presentation are as follows: Title:   ...

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 4:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial Officer, AmpliPhi Biosciences Todd Patrick - President and Chief Executive Officer, C3J Therapeutics Brian Varnum - Chief Development Officer, C3J Therapeutics Conference Call Participants Joe Pantginis - HC Wainwright Michael Higgins ...